| |
Axelar AB is a Swedish biotechnology company that focuses
its activities on research related to the insulin-like growth
factor-1 (IGF-1) receptor inhibitors and their applications
in important human diseases, especially cancer.
Axelar’s overall objective is to develop innovative
small-molecule compounds that inhibit the IGF-1 receptor for
treatment of IGF-1 receptor-dependent diseases where a significant
unmet medical need still exists.
Axelar has successfully completed its first Phase I/II clinical
study in advanced-stage cancer patients with solid tumors.
Axelar is now running a randomized Phase II program in patients
suffering from non-small cell lung carcinoma. |
|
Latest news
May 15, 2012
Axelar to present at the annual American Society of
Clinical Oncology (ASCO) meeting in Chicago in June 2012
READ
MORE
Press release December 28, 2011
Axelar initiates a Phase II clinical study with AXL1717
for the treatment of non-small cell lung cancer
READ
MORE
New poster presented at the European
Multidisciplinary Cancer Congress September 26, 2011
Phase I Dose-escalation Study of AXL1717: a Novel Targeted
Oral Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor
and Its Implications for Patients with Non-small Cell Lung
Carcinoma
READ
MORE
Press release September 26, 2011
Axelar reports good safety profile of AXL1717 in Phase
I/II in cancer patients
READ
MORE
Press release July 07, 2011
Axelar reports completion of the Phase I/II safety
study with AXL1717 in cancer patients
READ
MORE
See also News
|
|
